In case you missed it, my first “In Translation” column went live this week. As a companion to Xconomy’s regular life sciences coverage, this new column provides me with a chance to dive a little more deeply into strategic, cultural, and scientific topics around the biotech world. This week’s installment questions the relevance of traditional biotech venture capitalists in today’s scientifically rich but cash-constrained world. (Click here to check it out.) I welcome and encourage your feedback. Enjoy.